Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
102M
-
Shares change
-
+9.95M
-
Total reported value, excl. options
-
$1.83B
-
Value change
-
+$179M
-
Put/Call ratio
-
0.12
-
Number of buys
-
87
-
Number of sells
-
-50
-
Price
-
$18.01
Significant Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q2 2024
162 filings reported holding EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 102M shares
of 105M outstanding shares and own 96.47% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (15M shares), RA CAPITAL MANAGEMENT, L.P. (8.91M shares), Novo Holdings A/S (6.34M shares), BlackRock Inc. (6.02M shares), BAKER BROS. ADVISORS LP (5.84M shares), FMR LLC (4.78M shares), VANGUARD GROUP INC (4.51M shares), Frazier Life Sciences Management, L.P. (3.73M shares), Cormorant Asset Management, LP (3.01M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.87M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.